ReACT-BCG

ReACT-BCG is an experimental **CAR-T cell therapy** being developed by Longbow Immunotherapy for bladder cancer, particularly non-muscle-invasive bladder cancer treated with intravesical bacillus Calmette-Guérin. The construct is designed so adoptively transferred T cells recognize **BCG-associated antigens** rather than a conventional tumor cell surface antigen, with the goal of exploiting BCG already delivered into the bladder to locally reactivate and amplify antitumor T-cell activity within the tumor microenvironment. Public information indicates the program was reported in **preclinical mouse bladder cancer models**, where it improved survival, reduced tumor volume, and altered immune-cell markers; no clear evidence of clinical-stage human development was identified. Mechanistically, it is best understood as a BCG-directed CAR-T platform intended to synergize with intravesical BCG immunotherapy rather than as a standard antibacterial or standalone BCG product.

Other names

ReEnergized Adoptive Cell Transfer BCG